Valvular manifestations of human immunodeficiency virus infection - Results from the prospective, multicenter HIV-HEART study

Journal of Cardiovascular Medicine

Volumn 14, Issue 10, 2013, Pages 733-739

  Reinsch, Nico ^a   Esser, Stefan ^a   Gelbrich, Götz ^b   Brockmeyer, Norbert ^c   Potthoff, Anja ^c   Schadendorf, Dirk ^a   Erbel, Raimund ^a   Neumann, Till ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

AIDS; HIV infection; Valvular heart disease

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ANTIRETROVIRAL THERAPY; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; FEMALE; HEART VALVE REGURGITATION; HEART VALVE STENOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; TRANSTHORACIC ECHOCARDIOGRAPHY; TWO DIMENSIONAL ECHOCARDIOGRAPHY; VALVULAR HEART DISEASE; VIRUS LOAD;

ADULT; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDIES; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; GERMANY; HEART VALVE DISEASES; HEART VALVES; HEMODYNAMICS; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 84885415275     PISSN: 15582027     EISSN: 15582035     Source Type: Journal    
DOI: 10.2459/JCM.0b013e32835dc953     Document Type: Article

References (33)

1. Sabin CA, Worm SW, Weber R, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIVinfected patients enrolled in the D:A:D study: A multicohort collaboration. Lancet 2008; 371:1417-1426.
2. Torriani FJ, Komarow L, Parker RA, et al. Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s. J Am Coll Cardiol 2008; 52:569-576.
3. Friis-Moller N, Reiss P, Sabin CA et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356:1723- 1735.
4. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005; 352:48-62.
5. Holmberg SD, Moorman AC, Williamson JM et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002; 360:1747- 1748.
6. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4 count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283- 2296.
7. Meng Q, Lima JA, Lai H, et al. Use of HIV protease inhibitors is associated with left ventricular morphologic changes and diastolic dysfunction. JAIDS 2002; 30:306-310.
8. Guha S, Pande A, Mookerjee S, et al. Echocardiographic profile of ART naive human immunodeficiency virus (HIV) infected patients in a tertiary care hospital in Kolkata. Indian Heart J 2010; 62:330-334.
9. Cecchi E, Imazio M, Tidu M, et al. Infective endocarditis in drug addicts: role of HIV infection and the diagnostic accuracy of Duke criteria. J Cardiovasc Med (Hagerstown) 2007; 8:169-175.
10. Letts DP, Lopez-Candales A. Atypical echocardiographic findings of endocarditis in an immunocompromised patient. Echocardiography 2004; 21:715-719.
11. Smith DT, Sherwood M, Crisel R, et al. A comparison of HIV-positive patients with and without infective endocarditis: An echocardiographic study-the Emory Endocarditis Group experience. Am J Med Sci 2004; 328:145-149.
12. Valencia E, Miro J. Endocarditis in the setting of HIV infection. AIDS Rev 2004; 6:97-106.
13. Neumann T, Esser S, Potthoff A et al. Prevalence and natural history of heart failure in outpatient HIV-infected subjects: rationale and design of the HIVHEART study. Eur J Med Res 2007; 12:243-248.
14. Neumann T, Esser S, Potthoff A et al. Prevalence and natural history of heart failure in outpatient HIV-infected subjects: rationale and design of the HIVHEART study. Eur J Med Res 2007; 12:243-248.
15. Gottdiener JS, Bednarz J, Devereux R, et al. American Society of Echocardiography recommendations for use of echocardiography in clinical trials. J Am Soc Echocardiogr 2004; 17:1086-1119.
16. Zoghbi WA, Enriquez-Sarano M, Foster E, et al. Recommendations for evaluation of the severity of native valvular regurgitation with twodimensional and Doppler echocardiography. J Am Soc Echocardiogr 2003; 16:777-802.
17. Breuckmann F, Neumann T, Kondratieva J et al. Dilated cardiomyopathy in two adult human immunodeficiency positive (HIV) patients possibly related to highly active antiretroviral therapy (HAART). Eur J Med Res 2005; 10:395-399.
18. Garcia MJ, Thomas JD, Klein AL. New Doppler echocardiographic applications for the study of diastolic function. J Am Coll Cardiol 1998; 32:865-875.
19. Schuster I, Thoni GJ, Ederhy S, et al. Subclinical cardiac abnormalities in human immunodeficiency virus-infected men receiving antiretroviral therapy. Am J Cardiol 2008; 101:1213-1217.
20. Larsen MV, Omland LH, Gerstoft J, et al. Impact of injecting drug use on response to highly active antiretroviral treatment in HIV-1-infected patients: A nationwide population-based cohort study. Scand J Infect Dis 2010; 42:917-923.
21. Barbaro G. Cardiovascular manifestations of HIV infection. Circulation 2002; 106:1420-1425.
22. Barbaro G, Di Lorenzo G, Grisorio B, Barbarini G. Cardiac involvement in the acquired immunodeficiency syndrome: A multicenter clinicalpathological study. Gruppo Italiano per lo Studio Cardiologico dei pazienti affetti da AIDS Investigators. AIDS Res Hum Retroviruses 1998; 14:1071-1077.
23. Reinsch N, Buhr C, Krings P, et al. Effect of gender and highly active antiretroviral therapy on HIV-related pulmonary arterial hypertension: results of the HIV-HEART Study. HIV Med 2008; 9:550-556.
24. Degano B, Guillaume M, Savale L, et al. HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era. AIDS 2010; 24:67-75.
25. Damas JK, Otterdal K, Yndestad A, et al. Soluble CD40 ligand in pulmonary arterial hypertension: possible pathogenic role of the interaction between platelets and endothelial cells. Circulation 2004; 110:999-1005.
26. Akasaka T, Yoshikawa J, Yoshida K, et al. Age-related valvular regurgitation: A study by pulsed Doppler echocardiography. Circulation 1987; 76:262- 265.
27. Biava G, Delfino M, Lagana B, et al. Prevalence of valvular regurgitation in structurally normal hearts: A colour-Doppler study. Coron Artery Dis 1997; 8:559-563.
28. Yoshida K, Yoshikawa J, Shakudo M, et al. Color Doppler evaluation of valvular regurgitation in normal subjects. Circulation 1988; 78:840-847.
29. Klein AL, Burstow DJ, Tajik AJ, et al. Age-related prevalence of valvular regurgitation in normal subjects: A comprehensive color flow examination of 118 volunteers. J Am Soc Echocardiogr 1990; 3:54-63.
30. Choong CY, Abascal VM, Weyman J, et al. Prevalence of valvular regurgitation by Doppler echocardiography in patients with structurally normal hearts by two-dimensional echocardiography. Am Heart J 1989; 117:636-642.
31. Okura H, Takada Y, Yamabe A, et al. Prevalence and correlates of physiological valvular regurgitation in healthy subjects. Circ J 2011; 75:2699-2704.
32. Singh JP, Evans JC, Levy D, et al. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am J Cardiol 1999; 83:897-902.
33. Gray GW, Salisbury DA, Gulino AM. Echocardiographic and color flow Doppler findings in military pilot applicants. Aviat Space Environ Med 1995; 66:32-34.